Kirkland & Ellis advised SR One, a transatlantic life sciences investment firm, on the closing of its second fund (Fund II) at over $600 million, substantially exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline in 2020 to form a fully independent investment firm. The diverse investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds and family offices.

The Kirkland team was led by investment funds partners Jean Jeong, Brian Delaney, Katie St. Peters and Ted Ughetta and associates Sarah Nolan and Soo Young Hong and tax partner Steve Butler.